[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-332090-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-332090-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","osteosarcoma-arising-as-a-secondary-malignancy-following-treatment-for-hematologic-cancer-a-report-of-33-affected-patients-from-the-cooperative-osteosarcoma-study-group-coss","Osteosarcoma Arising as a Secondary Malignancy Following Treatment for Hematologic Cancer - A Report of 33 Affected Patients from the Cooperative Osteosarcoma Study Group (COSS)","","Purpose: Osteosarcoma may develop as a secondary malignancy after prior leukemias or lymphomas; this report aims to deepen understanding of these rare events. Patients and methods: The Cooperative Osteosarcoma Study Group database was searched for individuals whose osteosarcoma occurred after a previous hematological malignancy, documenting presentation, prior treatments, and outcomes. Key findings: Radiotherapy for the hematologic cancer emerged as a major risk factor; genetic tumor predispositions were identified in a subset. Modern interdisciplinary management appears feasible with adaptations after prior therapies, while prognosis is worse than in patients without preceding cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/osteosarcoma-arising-as-a-secondary-malignancy-following-treatment-for-hematologic-cancer-a-report-of-33-affected-patients-from-the-cooperative-osteosarcoma-study-group-coss/332090/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/osteosarcoma-arising-as-a-secondary-malignancy-following-treatment-for-hematologic-cancer-a-report-of-33-affected-patients-from-the-cooperative-osteosarcoma-study-group-coss/332090.png","ImageObject",300,407,{"name":42,"@type":43},"Eliana","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of this report on osteosarcoma after hematologic cancer?","Question",{"text":63,"@type":64},"To increase knowledge about rare secondary osteosarcoma events that arise after leukemias or lymphomas, and to document potential risk factors and outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the patients identified and what data were evaluated?",{"text":68,"@type":64},"Individuals developing osteosarcoma after a prior hematological malignancy were identified from the Cooperative Osteosarcoma Study Group database, with details on presentation, prior treatments, and outcomes.",{"name":70,"@type":61,"acceptedAnswer":71},"What treatment-related and biological factors were suggested by the findings?",{"text":72,"@type":64},"Radiotherapy given to treat the hematologic cancer appeared as a major risk factor, and genetic tumor predispositions were found in a subset of patients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},332090,1790193180,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":4},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","cancers   \nArticle  \nOsteosarcoma Arising as a Secondary Malignancy Following  \nTreatment for Hematologic Cancer: A Report of 33 Affected Patients from the Cooperative Osteosarcoma Study Group (COSS)  \nStefan S. Bielack 1,2, *, Vanessa Mettmann 1, Daniel Baumhoer 3, Claudia Blattmann 1, Birgit Burkhardt 2, Christoph K. W. Deinzer 4, Leo Kager 5,6, Matthias Kevric 1, Christine Mauz-Körholz 7,8, Peter Müller-Abt 9, Dirk Reinhardt 10, Alexandru-Anton Sabo 1, Martin Schrappe 11, Benjamin Sorg 1, Reinhard Windhager 12 and Stefanie Hecker-Nolting 1  \nCitation: Bielack, S.S.; Mettmann, V.; Baumhoer, D.; Blattmann, C.; Burkhardt, B.; Deinzer, C.K.W.; Kager, L.; Kevric, M.; Mauz-Körholz, C.; Müller-Abt, P.; et al. Osteosarcoma Arising as a Secondary Malignancy Following Treatment for Hematologic Cancer: A Report of 33 Affected Patients from the Cooperative Osteosarcoma Study Group (COSS) . Cancers 2024, 16, 1836. [https://](https://)[ ](https://)[doi.org/10.3390/cancers16101836](doi.org/10.3390/cancers16101836)  \nAcademic Editor: Anthony Elias  \nReceived: 22 March 2024  \nRevised: 12 April 2024  \nAccepted: 8 May 2024  \nPublished: 11 May 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Klinikum Stuttgart—Olgahospital, Stuttgart Cancer Center, Zentrum für Kinder-, Jugend-und Frauenmedizin, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), 70174 Stuttgart, Germany; [vanessa.mettmann@umm.de](vanessa.mettmann@umm.de) (V.M.); [c.blattmann@klinikum-stuttgart.de](c.blattmann@klinikum-stuttgart.de) (C.B.); [m.kevric@klinikum-stuttgart.de](m.kevric@klinikum-stuttgart.de) (M.K.); [a.sabo@klinikum-stuttgart.de](a.sabo@klinikum-stuttgart.de) (A.-A.S.); [b.sorg@klinikum-stuttgart.de](b.sorg@klinikum-stuttgart.de) (B.S.); [s.hecker-nolting@klinikum-stuttgart.de](s.hecker-nolting@klinikum-stuttgart.de) (S.H.-N.)  \n2 Klinik für Kinder-und Jugendmedizin, Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Münster, 48149 Münster, Germany; [birgit.burkhardt@ukmuenster.de](birgit.burkhardt@ukmuenster.de)  \n3 Knochentumor Referenzzentrum, Institut für Medizinische Genetik und Pathologie, Universitätsspital und Universität Basel, 4031 Basel, Switzerland; [daniel.baumhoer@usb.ch](daniel.baumhoer@usb.ch)  \n4 Abteilung Innere Medizin VIII—Medizinische Onkologie und Pneumologie, Universitätsklinikum Tübingen, 72076 Tübingen, Germany; christoph.deinzer@med.uni-tuebingen.de  \n5 St. Anna Kinderspital, Universitätsklinik für Kinder-und Jugendheilkunde der Medizinischen Universität Wien, 1090 Vienna, Austria  \n6 St. Anna Children’s Cancer Research Institute (CCRI), 1090 Vienna, Austria  \n7 Pädiatrische Hämatologie und Onkologie, Zentrum für Kinderheilkunde der Justus-Liebig-Universität, 35390 Gießen, Germany; [christine.mauz-koerholz@paediat.med.uni-giessen.de](christine.mauz-koerholz@paediat.med.uni-giessen.de)  \n[8](8 Medizinische Fakult)[ Medizinische Fakult](8 Medizinische Fakult)ä[t der Martin-Luther-Universit](t der Martin-Luther-Universit)ä[t Halle-Wittenberg](t Halle-Wittenberg), [06120 Halle](06120 Halle), [Germany](Germany)  \n[9](9 Radiologisches Institut)[ Radiologisches Institut](9 Radiologisches Institut) ([Kinderradiologie](Kinderradiologie)), Zentrum für Kinder-, Jugend-und Frauenmedizin, Klinikum Stuttgart—Olgahospital, 70174 Stuttgart, Germany; [p.mueller-abt@klinikum-stuttgart.de](p.mueller-abt@klinikum-stuttgart.de)  \n[10](10 Klinik f)[ Klinik f](10 Klinik f)ü[r Kinderheilkunde III](r Kinderheilkunde III), [Zentrum f](Zentrum f)ü[r Kinder-](r Kinder-)und Jugendmedizin, Universitätsmedizin Essen, 45147 Essen, Germany; [dirk.reinhardt@uk-essen.de](dirk.reinhardt@uk-essen.de)  \n11 Klinik für Kinder-und Jugendmedizin I, Campus Ki","cbCaiebZSjxRUbPy","https://ap.wps.com/l/cbCaiebZSjxRUbPy","pdf",549743,12,"English","# Simple Summary\n# Abstract\n## Purpose\n## Patients and methods","[{\"question\":\"What is the purpose of this report on osteosarcoma after hematologic cancer?\",\"answer\":\"To increase knowledge about rare secondary osteosarcoma events that arise after leukemias or lymphomas, and to document potential risk factors and outcomes.\"},{\"question\":\"How were the patients identified and what data were evaluated?\",\"answer\":\"Individuals developing osteosarcoma after a prior hematological malignancy were identified from the Cooperative Osteosarcoma Study Group database, with details on presentation, prior treatments, and outcomes.\"},{\"question\":\"What treatment-related and biological factors were suggested by the findings?\",\"answer\":\"Radiotherapy given to treat the hematologic cancer appeared as a major risk factor, and genetic tumor predispositions were found in a subset of patients.\"}]","Osteosarcoma Arising as a Secondary Malignancy Following Treatment for Hematologic Cancer - A Report of 33 Affected Patients from the Cooperative Osteosarcoma Study Group (COSS) | PDF",1789996700]